Study of H021 tablets for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests an experimental tablet called H021 for people with moderate to severe Crohn's disease that hasn't responded well to other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- You must have been diagnosed with Crohn's disease for at least 12 weeks
- Your Crohn's disease must be moderately to severely active, based on a special score and a colonoscopy showing active inflammation
- You must have tried and failed at least one prior treatment like steroids, immunosuppressants, or advanced therapies (e.g., anti-TNF drugs)
- If you are taking certain other Crohn's medications, you need to be on a stable dose before and during the study
- You must agree to use effective contraception if applicable and not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.